US-based Parse Biosciences, the leader in accessible and scalable single cell sequencing, has affirmed plans to proceed with development and future release of their Evercode single cell chromatin products. This comes on the heels of Parse invalidating the patents that 10x Genomics had asserted against Parse’s Evercode Whole Transcriptome products and the subsequent cancellation of a trial on those patents.
In connection with these events, Parse reached a favorable resolution with 10x Genomics over other patents that are unrelated to either Parse’s existing Evercode products or its forthcoming chromatin accessibility products.
Parse’s chromatin accessibility technology leverages a novel approach with advantages over existing methods such as ATAC-seq and will deliver higher quality, more uniform data. Parse plans to make their new solutions available for early access in late 2025.
Parse’s latest innovations include the recent launch of their Evercode Penta kit, the largest ever single cell sequencing kit that allows researchers to look at up to 5 Million cells in a single experiment.
